Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Operating Expenses:
Research and development	$ 2,122,610	$ 4,277,783	$ 4,384,850	$ 8,003,915
General and administrative	2,146,570	3,432,534	5,043,014	6,138,928
Total operating expenses	4,269,180	7,710,317	9,427,864	14,142,843
Operating loss	(4,269,180)	(7,710,317)	(9,427,864)	(14,142,843)
Other income (expense):
Other income (expense), net	193,654	4,828	371,192	(39,567)
Interest expense	(1,666)	(204,484)	(4,961)	(363,412)
Total other income (expense), net	191,988	(199,656)	366,231	(402,979)
Loss from continuing operations before benefit from income taxes and noncontrolling interests	(4,077,192)	(7,909,973)	(9,061,633)	(14,545,822)
Benefit from income taxes	0	(5,887,543)	0	(5,887,543)
Net loss from continuing operations	(4,077,192)	(2,022,430)	(9,061,633)	(8,658,279)
Discontinued operations - net of taxes	0	40,487,438	0	37,329,963
Net (loss) income	(4,077,192)	38,465,008	(9,061,633)	28,671,684
Less - net loss from continuing operations attributable to noncontrolling interests	(821)	(54,676)	(2,683)	(119,342)
Less - net loss from discontinued operations attributable to noncontrolling interests	0	(199,325)	0	(568,156)
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders	(4,076,371)	38,719,009	(9,058,950)	29,359,182
Amounts attributable to Caladrius Biosciences, Inc. common stockholders:
Loss from continuing operations	(4,076,371)	(1,967,754)	(9,058,950)	(8,538,937)
Discontinued operations - net of taxes	0	40,686,763	0	37,898,119
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders	$ (4,076,371)	$ 38,719,009	$ (9,058,950)	$ 29,359,182
Basic and diluted (loss) income per share
Continuing operations (in usd per share)	$ (0.42)	$ (0.22)	$ (0.95)	$ (0.99)
Discontinued operations (in usd per share)	0.00	4.56	0.00	4.38
Caladrius Biosciences, Inc. common stockholders (in usd per share)	$ (0.42)	$ 4.34	$ (0.95)	$ 3.39
Weighted average common shares outstanding:
Basic and diluted shares	9,591,958	8,926,783	9,577,195	8,657,334